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Summary  Carbapenem-resistant  Klebsiella  pneumoniae  (CRKP)  is  emerging  as  a
public  health  problem  worldwide.  In  Italy,  a  remarkable  increase  in  CRKP  cases
has  been  reported  since  2010.  In  this  study,  CRKP  diffusion,  distribution  and  in-
hospital  transmission  trends  were  evaluated  in  a university  hospital  in  Milan,  Italy,
from  January  2012  to  December  2013.  Isolates  from  63  newly  detected  CRKP-positiveKlebsiellapneumoniae;
patients  were  genotyped,  and  possible  transmission  was  determined  by  combiningCross-transmission;
Infections  control
measures;
the  molecular  results  with  data  concerning  the  patients’  admission  and  in-hospital
transfers.  Most  of  the  cases  (90.4%)  were  from  general  medical  and  surgery  wards,
and  the  remaining  9.6%  were  from  the  intensive  care  unit.  Fifteen  of  the  46  hospital-
associated  cases  (32.6%)  were  attributable  to  in-hospital  transmission.  After  the
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introduction  of  targeted  and  hospital-wide  control  measures,  the  transmission  index
signiﬁcantly  decreased  from  0.65  to  0.13  (p  =  0.01).  There  was  also  a  decrease  in  the
overall  nosocomial  case  incidence,  from  0.37  to  0.17  per  1000  person-days  (p  =  0.07).
Our  ﬁndings  indicate  that  the  spread  of  CRKP  in  Northern  Italy  hospitals  may  go  far
 (i.e.,  intensive  care  units)  and  that  strict  surveillance  should
areas  of  care.
Active  surveillance;
Active  screening
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
I
C
(
t
c
m
w
C
l
c
i
h
i
t
a
p
a
[
h
p
w
b
C
H
b
p
[
d
u
i
h
F
R
t
c
1
b
s
m
b
p
s
d
a
t
d
M
S
L
i
p
w
c
t
t
(
u
w
w
e
m
e
S
T
i
D
c
a
g
o
t
hospital admission  and  the  date  of  the  ﬁrst  CRKP
detection;  the  admission  ward  and  any  inter-ward
transfers; and  the  discharge  or  death  date.beyond  high-risk  settings
be  extended  to  general  
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arbapenem-resistant  Klebsiella  pneumoniae
CRKP), the  resistance  of  which  is  largely  due
o broad-spectrum  -lactamase  production  (i.e.,
arbapenemases)  [1], are  becoming  some  of the
ost challenging  multidrug-resistant  pathogens
orldwide [1—3]. Infections  that  are  caused  by
RKP are  difﬁcult  to  treat  because  of  the  very
imited treatment  options  that  are  available,  which
onsequently  often  lead  to  poor  patient  outcomes,
ncreased morbidity  and  mortality,  and  higher
ospital costs  [4—6]. Hospitals  are  particularly
mportant  reservoirs  of  these  pathogens  because  of
he combination  of  seriously  ill  patients,  intensive
ntibiotic use,  and  close  patient/patient  and
atient/healthcare  worker  contact,  which  encour-
ge the  spread  of  CRKP  and  infectious  outbreaks
7—11].
Bundled  interventions  consisting  of  strict  hand
ygiene, the  isolation  of  infected  or  colonized
atients, and  the  active  surveillance  of  high-risk
ards, such  as  intensive  care  units  (ICUs),  have
een recommended  as  key  strategies  for  preventing
RKP transmission  in  healthcare  facilities  [12,13].
owever, there  is  little  evidence  as  to  what  is  the
est and  most  sustainable  preventive  approach,
articularly in  contexts  in  which  CRKP  is  endemic
14,15],  which  may  at  least  partially  explain  the
isparity in  the  infection  control  practices  that  are
sed in  different  hospitals  [16,17].
The CRKP  infection  number  has  sharply  increased
n Italy  over  recent  years  [18,19],  and  a  series  of
ospital  outbreaks  have  been  described  [20—22].
urthermore,  data  from  the  European  Antimicrobial
esistance Surveillance  Network  (EARS-Net)  shows
hat the  overall  proportion  of  CRKP  isolates  from
linical specimens  increased  from  2.2%  in  2009  to
9.4% in  2012  [18].  However,  the  CRKP  infection
urden varies  widely  from  hospital  to  hospital,  pos-
ibly because  of  location,  case  mix,  and  human  and
aterial resource  differences  [18].
Following  an  increase  in  the  CRKP  infection  num-
er at  our  hospital,  we  introduced  a  hospital-wide
C
d
hrotocol  for  implementing  a set  of  control  mea-
ures in  January  2013.  The  aim  of  this  paper  was  to
escribe the  trends  of  newly  detected  CRKP  cases
nd the  relative  contribution  of  patient-to-patient
ransmission  in  the  year  prior  to  and  after  its  intro-
uction.
ethods
etting
uigi  Sacco  Hospital  is  a university  teaching  hospital
n Milan,  Italy,  which  admits  an  average  of  20,000
atients  per  year.  It  has  506  licensed  beds  in  27
ards,  each  of  which  has  its  own  dedicated  medi-
al and  nursing  staff,  including:  339  beds  belonging
o 19  medical  (mainly  internal  medicine  and  infec-
ious disease)  wards;  159  to  eight  surgery  wards
general  surgery,  cardiac  surgery,  orthopedics  and
rology),  and  eight  to  a single  ICU.  The  medical
ards have  rooms  with  2—3  beds,  all  of the  surgery
ards have  rooms  with  two  beds,  and  the  ICU  has
ight single  cubicles.  During  the  study  period,  the
ean individual  patient  hospital  stay  duration  was
ight days.
tudy design and deﬁnitions
his  study  retrospectively  analyzed  all  of  the  newly
dentiﬁed  CRKP  cases  between  January  1,  2012,  and
ecember 31,  2013.
A  case  patient  was  deﬁned  as  someone  whose
linical or  screening  samples  led  to  CRKP  isolation,
nd a  record  was  made  of  each  case  patient’s  age,
ender,  major  underlying  disease(s),  and  history
f hospitalizations  and/or  antibiotic  treatments  in
he previous  three  months;  the  date  of  the  currentThe patients  who  were  identiﬁed  as  having
RKP within  the  ﬁrst  72  h  of  admission  were
eﬁned as  community-associated  cases  or  imported
ealthcare-associated  cases  if  they  had  been
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exposed  to  healthcare  settings  during  the  previous
three months;  those  identiﬁed  by  means  of  a cul-
ture that  was  obtained  72  h  after  hospital  admission
were deﬁned  as  hospital-associated  cases.
The patients  who  had  stayed  in  the  same  hos-
pital ward  during  overlapping  periods  or  within  a
maximum  time  window  of  four  weeks  were  deﬁned
as being  epidemiologically  linked  [23]. In-hospital
transmission was  considered  to  have  occurred  if
genotypically  related  strains  were  detected  in  the
epidemiologically  linked  patients  in  whom  CRKP
isolates  were  ﬁrst  detected  more  than  72  h after
admission. The  transmission  index  was  calculated
as the  number  of  cases  that  were  attributable  to
transmission  (secondary  cases)  divided  by  the  num-
ber of  cases  that  were  not  acquired  by  transmission
(primary cases).
The hospital-associated  CRKP  case  incidence  was
calculated  as  the  number  of  new  cases  per  1000
person-days of  hospitalization  for  the  semester.
Microbiological testing
Isolates  that  were  obtained  from  routine  micro-
biological cultures  of  relevant  clinical  samples
(e.g., urine,  wound  exudates,  bronchial  secre-
tions, blood,  and  peritoneal  ﬂuid)  were  identiﬁed
at the  species  level  and  tested  for  antimi-
crobial susceptibility  using  the  automated
Vitek 2 system  (BioMérieux,  Marcy  l’Etoile,
France). The  tested  antimicrobials  included
beta-lactams  (ampicillin,  amoxicillin-clavulanate,
piperacillin-tazobactam,  cefoxitin,  cefotaxime,
ceftazidime, cefepime,  imipenem,  meropenem,
and ertapenem),  quinolones  (ciproﬂoxacin),
aminoglycosides  (amikacin  and  gentamicin),  and
trimethoprim/sulfamethoxazole.  Susceptibility
to colistin  and  tigecycline  was  veriﬁed  with
the E-test  (BioMérieux,  Marcy  l’Etoile,  France).
Interpretation of  the  susceptibility  patterns  was
performed  according  to  the  European  Committee
on Antimicrobial  Susceptibility  Testing  (EUCAST)
breakpoints [24].
Rectal  swabs,  which  were  collected  for
epidemiological  purposes,  were  screened  for
carbapenemase-producing  Enterobacteriaceae  by
direct inoculation  in  selective  chromogenic  agar,
ChromID  Carba  (BioMérieux  Marcy  l’Etoile,  France).
The presumptive  carbapenemase-producing  Enter-
obacteriaceae  colonies  were  identiﬁed  by  color
appearance according  to  the  manufacturer’s
instructions.  Suspected  colonies  were  subcultured
onto blood  agar  plates  and  were  submitted  to
identiﬁcation  and  susceptibility  testing  with  the
Vitek 2 automated  system.
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henotype testing
henotype  testing,  which  was  utilized  to  differen-
iate  between  the  -lactam  resistance  mechanisms
n the  CRKP  isolates,  was  performed  with  a
ouble-disk  synergy  test  (KPC  + MBL  Conﬁrm  ID  kit,
osco Diagnostica  A/S,  Taastrup,  Denmark).  The
it consists  of  four  tablets  containing  meropenem
substrate), meropenem  +  aminophenylboronic
cid (an  K.  pneumoniae-carbapenemase  inhibitor),
eropenem  +  dipicolinic  acid  (an  metallo--
actamase inhibitor)  and  meropenem  +  cloxacillin
an AMPc--lactamase  inhibitor).  Brieﬂy,  a  pure
ulture  suspension  of  the  isolate  that  was  to  be
ested was  plated  on  a  Muller  Hinton  agar  plate.
he four  tablets  were  placed  on  the  inoculated
gar plate  at  a  sufﬁcient  distance  to  allow  for
roper inhibitory  zone  measurements.  After  an
vernight  incubation  at  +37 ◦C,  the  inhibitory  zones
ere measured  and  compared  according  to  the
anufacturer  instructions.
olecular typing
ll  of  the  initial  CRKP  isolates  from  each
atient were  genotyped  with  automated  repetitive
xtragenic palindromic  polymerase  chain  reaction
rep-PCR)  (DiversiLab  system,  BioMérieux  Marcy
’Etoile,  France).  The  band  patterns  were  com-
ared  with  the  Pearson’s  correlation  method  with
he DiversiLab  web-based  software.  The  isolates
hat had  band  patterns  that  were  at  least  95%  sim-
lar were  considered  to  be  genetically  related  [25].
nfection control measures during the study
eriod
ospital-wide  policies  to  prevent  nosocomial
arbapenem-resistant  Enterobacteriaceae  trans-
issions were  introduced  in  January  2013  on  the
asis of  an  institutional  protocol  that  was  devel-
ped in  accordance  with  the  American  Centers  for
isease Control  and  Prevention  (CDC)  indications
12]. The  provisions  included  the  isolation  of  all
RKP-infected  or  CRKP-colonized  patients  in  single
ooms, hand  hygiene  enforcement  (hydro-alcohol
ispensers were  placed  at the  entrance  to  all
atient rooms)  and  environmental  cleaning;  the  use
f dedicated  patient  care  equipment;  and  the  use  of
isposable gloves  and  aprons.  Rectal  swab  screen-
ng was  indicated  for  all  of  the  patients  who  were
dmitted  to  the  ICU,  patients  with  a previous  CRKP
nfection/colonization  history  upon  admission,  and
oommates of the  patients  who  were  diagnosed
s having  hospital-  or  community-acquired  CRKP
nfections.  The  isolation  measures  were  maintained
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Figure  1  Temporal  distribution  of  newly  detected  patients  who  were  infected  or  colonized  with  carbapenem-resistant
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elebsiella  pneumoniae  by  hospital  ward  type  (L.Sacco  Ho
ntil  negative  results  were  obtained  from  at  least
hree clinical  and/or  screening  specimens  that
ere collected  at  three-day  intervals.
The microbiology  laboratory  activated  an  auto-
ated  alert  system  that  sent  e-mails  to  physicians
nd nurses  in  charge  of  the  patient’s  ward  and
he members  of  the  hospital  infection  control  team
HICT)  as  soon  as  a  CRKP  strain  was  identiﬁed  to
rompt immediate  actions  according  to  the  pro-
ocol.  Two  HICT  members  were  responsible  for
ontacting and/or  visiting  the  wards  in  which  new
RKP infection  cases  were  detected  to  promote
ull compliance  with  the  recommendations  and  to
erify the  presence  of  all  of  the  equipment  and
aterials.
tatistical analysis
he  Chi-squared  test  was  used  to  assess  the  trans-
ission  index  differences  in  the  year  prior  to  and
fter the  control  policy  introduction.
A Poisson  regression  was  used  to  compare
he new  hospital-associated  case  incidence  per
emester.
The SPSS  statistical  software,  version  11.0,  was
sed for  all  of  the  analyses,  and  a  p  value  of  0.5  or
ess was  considered  to  be  statistically  signiﬁcant.
esults
atient data
uring  the  study  period,  CRKP  was  detected  in
3 patients.  No  cases  were  recorded  in  the  ﬁrst
ve months  of  2012;  however,  between  June  and
ecember,  28  patients  were  found  to  be  infected
r colonized,  with  a  peak  of  10  cases/month
1
h
p
tal,  Milan,  2012—2013).
eing  recorded  in  October  and  November.  Between
anuary and  December  2013,  35  additional  cases
ere identiﬁed  at  an  average  rate  of  three
ases/month.
Thirty-seven patients  (58.7%)  were  hospitalized
n medical  wards,  20  (31.8%)  were  in  surgery/post-
urgery rehabilitation  wards,  and  six  (9.5%)  were  in
he ICU.  Overall,  14  of  the  27  hospital  wards  had  at
east one  CRKP-positive  patient.  Fig.  1  shows  the
emporal  distribution  of  the  newly  detected  cases
y hospital  ward  type.
Most  of  the  patients  were  elderly  (median
ge, 75  years,  range  22—91)  and  had  debilitating
nderlying neurocognitive  disorders  (38%),  cancer
33%), diabetes  mellitus  (27%),  chronic  gastroin-
estinal diseases  (25%),  cardiovascular  diseases
22%),  chronic  obstructive  pulmonary  disease  (21%),
nd/or chronic  renal  diseases  (21%).  Clinically
evere infections  occurred  in  four  patients  who
ere aged  <50  years  with  immunodeﬁciency  disor-
ers (three  with  HIV  infections  and  one  with  Crohn’s
isease).
Fifty-six  patients  (88%)  had  been  admitted  to
ealthcare  facilities  in  our  metropolitan  area  dur-
ng the  three  months  preceding  the  CRKP  isolation:
2% to  hospitals  (19.4%  to  ICUs)  and  38%  to  long-
erm care  facilities.  During  the  same  period,  53  of
he 63  CRKP-positive  patients  (84%)  had  received
road-spectrum antibiotics  (mainly  ceftriaxone,
iproﬂoxacin,  or  piperacillin-tazobactam).
CRKP  was  isolated  late  (after  a median  of  25
ays, range  7—89)  during  the  hospital  stays  in  46
f the  patients  (73%);  therefore,  they  were  consid-
red to  be  hospital-associated  cases.  The  remaining
7 cases  (27%)  were  categorized  as  being  imported
ealthcare-associated  cases,  and  only  two  of  these
atients  had  a previously  documented  CRKP  infec-
ion/colonization.
h
c
w
3
p
t
t
e
o
s
t
t
(
s
i
t
w
w
b
i
p
m
n
i
t
J
T
T
t
d
i
p
p
2
0
D
C
b
t
w
i
[
i
p
i28  
The  median  hospital  stay  duration  was  40  days
(range 5—201).  Eleven  patients  (17.4%)  died  dur-
ing their  hospitalization:  two  were  colonized  by
CRKP and  nine  had  severe  diseases  that  were  caused
by CRKP,  including  sepsis  (n  =  2),  hospital-acquired
pneumonia  (n  =  2),  chronic  wound  infections  (n  =  2),
peritonitis  (n  =  2),  and  pyelonephritis  (n  =  1).
CRKP isolates
In most  cases,  CRKP  was  isolated  from  clinical  sam-
ples: urine  (n  = 26,  41.3%),  surgical  exudates  (n  =  9,
14.3%) or  chronic  wounds  (n  =  6,  9.5%),  bronchial
secretions (n  =  8,  12.7%),  blood  (n  =  3,  4.8%),  and
peritoneal  ﬂuid  (n  = 2,  3.2%).  Nine  patients  had
CRKP that  was  detected  from  rectal  swabs:  ﬁve
were roommates  of  patients  with  a  CRKP  infection
and four  were  patients  who  were  screened  upon
admission to  the  ICU.
All  of  the  CRKP  isolates  were  resistant  to  -
lactams and  ciproﬂoxacin;  however,  most  were
intermediately  susceptible  to  gentamicin  and
tigecycline,  all  but  three  were  susceptible  to
colistin,  and  only  one  was  sensitive  to  trimetho-
prim/sulfamethoxazole  (Fig.  2).  Forty  isolates
(63.5%) were  fully  sensitive  to  only  colistin,  one
was sensitive  to  only  tigecycline  (1.6%),  and  two
(3.1%) were  resistant  to  all  of  the  tested  antibiotics,
including colistin.  All  of  the  isolates  were  phenotyp-
ically conﬁrmed  as  carbapenemase  producers.
Genotyping  revealed  six  distinct  cluster  patterns
and eight  singletons.  Twenty-seven  isolates  were
deﬁned  as  clone  A,  11  as  clone  B,  10  as  clone  C,
three as  clone  D,  two  as  clone  E,  and  two  as  clone
F (Fig.  2).  There  were  no  signiﬁcant  variations  in  the
antimicrobial  susceptibility  of  the  different  clones.
Amongst  the  major  clones,  A,  B  and  C,  6/27  (22.2%),
2/11 (18.2%)  and  2/10  (20%)  of  the  isolates  were
resistant  to  gentamicin,  and  10/27  (37%),  25/11
(18,2%)  and  4/10  (40%)  were  resistant  to  tigecy-
cline, respectively.  Two  of  the  three  isolates  that
were resistant  to  colistin  belonged  to  major  clones
A and  B,  and  one  was  a  singleton.  There  was  no  spe-
ciﬁc association  between  the  clinical  severity  of  the
CRKP infections  (as  deﬁned  by  fatal  outcomes)  and
isolate genotypes  (pattern  A  =  2 cases;  patterns  B,
C and  F  =  1 case  each;  and  singletons  = 4  cases).
Genotypic relatedness of the isolates that
were recovered from epidemiologically
linked  patientsTable  1  summarizes  the  epidemiological  charac-
teristics  of  the  cases  and  the  genotype  proﬁles
of the  isolates.  The  isolates  of  most  of  the
g
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ospital-associated  (93.5%)  and  imported  (70.5%)
ases belonged  to  one  of  the  six  cluster  groups,
ith a clear  prevalence  of  clone  A  (45.6%  and
5.2%, respectively).  A  comparison  of  the  genotype
atterns  of  the  isolates  that  were  obtained  from
he 31  patients  who  were  epidemiologically  linked
o other  CRKP-positive  patients  made  it  possible  to
stimate that  a  transmission  event  occurred  in  15
f the  46  hospital-associated  cases  (32.6%).  Fig.  2
hows  the  transmission  indices  before  and  after
he introduction  of  the  control  protocol.  Most  of
he cases  that  were  attributable  to  transmission
n =  11)  occurred  in  2012,  before  the  control  mea-
ures  had  been  implemented.  Six  of  these  occurred
n one  general  surgery  ward  and  ﬁve  occurred  in
he medical  wards  (four  in  the  internal  medicine
ards and  one  in  an  infectious  disease  ward)  to
hich two  CRKP-infected  surgical  patients  had
een transferred.  The  four  transmission  episodes
n 2013  (each  including  one  index  case  and  only  one
ossible secondary  case)  occurred  in  three  internal
edicine  wards  and  one  infectious  disease  ward.
Fig.  3  shows  that  the  transmission  index  sig-
iﬁcantly decreased  from  0.65  (95%CI:  0.41—0.83)
n the  period  between  June  and  December  2012
o 0.13  (95%CI:  0.05—0.28)  in  the  period  between
anuary and  December  2013  (p =  0.01).
he hospital-associated case incidence
here  was  also  a  trend  toward  a  decrease  in
he overall  hospital-associated  CRKP  case  inci-
ence from  a peak  of  18  per  72,888  person-days
n the  last  six  months  of  2012  (incidence  0.37
er 1000  person-days;  95%CI:  0.23—0.51)  to  10
er 75,185  person-days  in  the  last  six  months  of
013 (incidence  0.17  per  1000  person-days;  95%CI:
.08—0.27)  (p  = 0.07)  (Fig.  4).
iscussion
arbapenem-resistant  K.  pneumoniae  poses  a  num-
er of  challenges  in  terms  of  infection  control  and
reatment,  particularly  in  countries  such  as  Italy
here it  has  rapidly  become  endemic  and  there
s a considerable  likelihood  of  infectious  outbreaks
20—22].
Most of  the  63  CRKP-positive  cases  that  were
dentiﬁed in  our  study  over  an  18-month  period
redominately involved  elderly  patients  with  debil-
tating clinical  conditions  who  were  hospitalized  in
eneral surgery  and  medical  wards.  These  ﬁndings
re in  line  with  those  of  recent  studies  show-
ng that  the  spread  of  CRKP  in  Italy  is becoming
 matter  of  concern  in  areas  of  care  that  were
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Figure  2  Dendrogram  of  repetitive  sequence-based  polymerase  chain  reaction  patterns  and  the  antimicrobial  sus-
ceptibility  of  the  observed  carbapenem-resistant  Klebsiella  pneumoniae  isolates.  IMP  =  imipenem,  MEM  =  meropenem,
ETP  =  ertapenem,  CIP  =  ciproﬂoxacin,  STX  =  trimethoprim-sulfamethoxazole,  AMK  =  amikacin,  GEN  =  gentamicin,  TGC=
tigecycline,  CST  =  colistin.  S  =  sensitive,  I =  intermediate,  R  =  resistant.
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Table  1  The  epidemiological  characteristics  and  the  genotypic  proﬁles  of  isolates  from  the  63  observed  patients
who  were  infected  or  colonized  with  carbapenem-resistant  Klebsiella  pneumoniae  (L.Sacco  Hospital,  Milan,
2012—2013).
CRKP
genotype
pattern
Case  numbers
Overall  Hospital-
associated
cases
Imported
cases
Epidemiologically
linked cases
Non-
epidemiologically
linked  cases
Possibly
transmitted  on
the  basis  of
epidemiological
linkage  and
genotyping
Clone  A 27  21  6  16  5  14
Clone  B 11  7  4  2  5  —
Clone  C 10  9  1  6  4  1
Clone  D  3  2  1  1  2  —
Clone  E  2  2  —  1  1  —
Clone  F  2  2  —  1  1  —
Singleton  8  3  5  2  2  —
Total  63  46  17  31  20  15
Figure  3  Carbapenem-resistant  Klebsiella  pneumoniae  transmission  indices  before  (January—December  2012)  and
after  (January—December  2013)  the  introduction  of  a  hospital-wide  infection  control  protocol.
Figure  4  The  hospital-associated  infection  or  colonization  incidence  due  to  carbapenem-resistant  Klebsiella  pneu-
moniae  before  (January—December  2012)  and  after  (January—December  2013)  the  introduction  of  a  hospital-wide
infection  control  protocol.
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siffusion  and  transmission  of  CRKP  
enerally  considered  to  be  at  lower  risk  in  which
ne of  the  principal  targets  (and  consequently  a
ajor reservoir)  of  CRKP  is  the  geriatric  popula-
ion [26—28].  A  possible  change  in  the  epidemiology
f carbapenem-resistant  Enterobacteriaceae  from
raditional high-risk  settings  (i.e.,  ICUs)  to  general
are patients  is  also  suggested  to  be  a  result  of
he study  ﬁndings  that  were  conducted  in  other
ountries. Poulou  et  al.  [29]  reported  that  41%
f 73  CRKP  infections  registered  between  2009
nd 2011  at  a  university  hospital  in  Greece  were
dentiﬁed  in  medical  wards  and  15%  in  surgical
ards. Additionally,  during  a  hospital-wide  CRKP
nfection  outbreak  in  Israel,  the  neurology  and
eriatric  wards  were  amongst  the  most  involved
ards [11],  and  a  recent  state-wide  survey  of
arbapenem-resistant  Enterobacteriacae  in  Michi-
an (USA)  found  that  49%  of  the  cases  were
etected in  patients  who  were  admitted  to  the  gen-
ral care  ward  [30].
Almost  all  of  our  patients  had  a  history  of  hospi-
alizations and/or  stays  in  long-term  care  facilities
LTCF)  in  the  Milan  metropolitan  area,  and  the  fact
hat CRKP  was  isolated  early  during  the  hospital
tay of  27%  (within  72  h)  of  these  patients  suggests
hat a  substantial  proportion  of  all  of  the  CRKP
ases detected  in  our  region  may  be  due  to  the
ospital admission  of  patients  who  were  previously
olonized or  infected  with  CRKP.  Patient  move-
ents amongst  the  healthcare  facilities  belonging
o a  regional  healthcare  system  can  play  an  impor-
ant role  in  the  spread  of  antimicrobial  resistance
31],  and  it  was  found  that  the  introduction  and
issemination  of  CRKP  in  acute  care  hospitals  that
ere affected  by  recently  described  outbreaks
ere related  to  the  transfer  of  infected  or  colo-
ized patients  from  LTCFs  [32,33].
To deﬁne  the  CRKP  epidemiology  in  our  hospital
nd to  monitor  the  transmission  events  rapidly,  the
RKP strains  were  analyzed  with  a  semi-automated
ep-PCR system  that  had  a  high  discriminatory
ower in  detecting  clonal  relationships  during  a
acterial outbreak  [34].  The  molecular  results
howed that  most  of  the  CRKP  isolates  belonged
o three  major  clusters  of  genetically  related
roups, and  the  data  regarding  the  typical  spread
f CRKP  (i.e.,  the  transmission  of  identical  strains
etween  epidemiologically  linked  patients)  indi-
ated that  32%  of  the  hospital-associated  cases
ere attributable  to  cross-transmission.  However,
t is  important  to  note  that  the  mechanisms
nderlying  the  spread  of  carbapenem-resistance
n  Enterobacteriaceae  are  complex  and  that  epi-
emics  may  be  due  to  the  horizontal  transmission
f plasmids  rather  than  clones  [35].  Further  stud-
es using  more  sophisticated  and  costly  molecular
F
N31
echniques  are  therefore  needed  to  clarify  the
uestion.
The fact  that  the  number  of  possible  CRKP
ransmissions was  highest  in  2012  (transmission
ndex 0.64)  probably  reﬂects  the  inadequacy  of  the
nfection control  measures  in  our  general  surgi-
al and  medical  wards  because  the  hospital-wide
ntroduction  of  our  early  warning  alarm  system
nd the  implementation  of a  protocol  promoting
and hygiene  and  ensuring  the  prompt  adoption
f precautionary  measures  (including  the  isolation
f CRKP-positive  patients  in  separate  rooms)  in
anuary 2013  was  followed  by  a  signiﬁcant  reduc-
ion in  transmission  events.
Although  no  major  outbreaks  of  CRKP  occurred
fter the  introduction  of  the  control  measures,
he overall  incidence  of  hospital-associated  CRKP
ases did  not  signiﬁcantly  decrease.  This  indicated
he possible  presence  of  unrecognized  transmis-
ions due  to  a hidden  reservoir  of  asymptomatic
arriers. A  number  of  studies  in  high-risk  health-
are settings,  such  as  ICUs,  have  found  that  active
urveillance  that  is  aimed  at  identifying  patients
ith asymptomatic  gut  colonization  can  be  crucial
n controlling  the  spread  of  CRKP  [36,37]. Con-
equently,  in  accordance  with  the  CDC  guidelines
12], we  introduced  the  active  screening  of  rec-
al swabs  that  were  taken  from  patients  who  were
dmitted  to  our  ICU  and  patients  with  a known  his-
ory of  CRKP  colonization/infection  at  admission  as
ell as  from  the  roommates  of  newly  discovered
RKP-positive  patients.  However,  this  probably  only
rovided limited  information  regarding  the  real
xtent  of  colonization  pressure  because  most  of  our
RKP cases  occurred  in  non-ICU  wards,  and  many
f these  were  not  associated  with  close  contacts
etween patients.
In  conclusion,  our  ﬁndings  highlight  the  impor-
ance of  hospital  protocols  for  preventing  and
ontrolling CRKP  transmission  and  suggest  that
ctive CRKP  screening  in  endemic  regions  should
e extended  to  subsets  of  at-risk  patients  who
re admitted  to  general  care  wards,  particu-
arly those  transferred  from  other  hospitals  or
TCFs;  to  those  with  a recent  history  of  broad-
pectrum antibiotic  treatments;  and  to  older
atients with  chronic  debilitating  diseases.  Further
tudies are  needed  to  clarify  the  risk  factors  that
an better  identify  candidates  for  CRKP  screen-
ng and  to  deﬁne  the  cost-effectiveness  of  such  a
trategy.unding
o  funding  sources.
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